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1. Materials and methods
The chemicals and solvents were purchased from Rathburn, Sigma-Aldrich and Scharlau, and 
used without further purification. Fmoc Rink-amide MBHA resin and Fmoc-protected amino 
acids were purchased from Iris Biotech. Fluorescent dye PromoFluor-647 NHS ester was 
purchased from PromoKine.
1H and 13C NMR spectra were taken on Bruker AC 200P and Bruker 400 MHz spectrometers. 
High resolution mass spectra of all synthesized compounds were measured on Thermo 
Electron LTQ Orbitrap mass spectrometer. Thermo Scientific NanoDrop 2000c was used for 
measuring UV-VIS spectra and quantification of the products. Purification of peptide 
conjugates was performed with Schimadzu LC Solution (Prominence) system with manual 
injector and a diode array (SPD M20A) detector. Separation was achieved with a Gemini C18 
5 µm column (250  4.6 mm i.d., Phenomenex) protected by a 5 µm Gemini C18 4  2.0 mm 
guard column. 
Kinases: 
Pim-1 kinase,1 PKAc (bovine full length)2 and CK2α (amino acids 1-335)3 were expressed 
and purified as described previously.
SI (3)
2. Synthesis of ARC-compounds
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Scheme S1. Synthesis of 2,1,3-benzoselenadiazole-5-carboxylic acid (1) and 
2,1,3-benzoselenadiazole-4- carboxylic acid (2).
Synthesis of 2,1,3-benzoselenadiazole-5-carboxylic acid (1)
3,4-Diamino-benzoic acid 151 mg (1 mmol) was dissolved in 3.5 ml of 1M HCl and heated to 
80 °C, thereafter 222 mg (2 mmol) of selenium dioxide in 1.5 ml of water was added. The 
mixture was stirred for 2 h and the brown precipitate was separated, washed with water and 
dried to get the compound 1 (95%).
1H NMR (200 MHz, DMSO6d) δ 7.89-8.01 (2H, m), 8.43 (1H, s), 13.40 (1H, br).
13C NMR (50 MHz, DMSO6d) δ 123.1, 125.3, 127.8, 131.2, 159.1, 160.6, 166.7.
ESI-HRMS m/z calcd for C7H4N2O2Se [M+H]+ 228.95108, found 228.95103.
Synthesis of 2,1,3-benzoselenadiazole-4- carboxylic acid (2)
Synthesis of 2 was performed by the procedure described for 1, starting from 2,3-diamino-
benzoic acid. Yield 97%.
1H NMR (200 MHz, DMSO6d) δ 7.65 (1H, dd, J = 9.0 Hz and 6.8 Hz), 8.07-8.14 (2H, m), 
13.2 (1H, br).
13C NMR (50 MHz, DMSO6d) δ 125.6, 127.4, 128.3, 132.3, 156.4 160.1, 165.8.
ESI-HRMS m/z calcd for C7H4N2O2Se [M+H]+ 228.95108, found 228.95087.
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Scheme S2. Synthesis of 1,2,5-selenadiazolo[3,4-g]indol-yl-acetic acid (6) and 
1,2,5-Selenadiazolo[3,4-g]indol-yl-octanoic acid (7)
Compound 3 (1 eq) and K2CO3 (1.5 eq) in 4 ml of DMF were stirred at room temperature for 
10 min, then ethyl bromoacetate or isopropyl ester of 8-bromooctanoic acid (1.2 eq) was 
added. The reaction mixture was stirred at room temperature overnight. The reaction was 
quenched by the addition of water. The mixture was partitioned between EtOAc and brine. 
The organic layer was dried over Na2SO4, filtered and concentrated. The esters (4 and 5) were 
treated with 4 M NaOH/ethanol at 60 C. After 3 h the reaction mixture was neutralized with 
1 M HCl, then partitioned between EtOAc and brine. The organic layer was dried over 
Na2SO4, concentrated and purified by silica gel column chromatography to yield acids 6 
(65%) and 7 (47%).
1,2,5-Selenadiazolo[3,4-g]indol-yl-acetic acid (6):
1H NMR (200 MHz, DMSO6d) δ 5.48 (2H, s), 6.57 (1H, d, J = 
2.8 Hz), 7.35 (1H, d, J = 9.2 Hz), 7.42 (1H, d, J = 2.8 Hz), 
7.74 (1H, d, J = 9.2 Hz), 13.03 (1H, br). 13C NMR (50 MHz, 
DMSO6d) δ 50.0, 104.1, 115.6, 125.0, 125.9, 126.8, 129.4, 
150.8, 159.8, 170.2. HRMS m/z calcd monoisotopic mass for C10H7N3O2Se 280.97035, 
found: 280.97037.
1,2,5-Selenadiazolo[3,4-g]indol-yl-octanoic acid (7):
1H NMR (400 MHz, CDCl3) δ 1.37 (6H, m), 1.61 (2H, quin, J = 
7.2 Hz), 1.94 (2H, quin, J = 7.2 Hz), 2.32 (2H, t, J = 7.2 Hz), 
4.71 (2H, t, J = 7.2 Hz), 6.49 (1H, d, J = 2.8 Hz), 7.10 (1H, d, J 
= 2.8 Hz), 7.37 (1H, d, J = 9.2 Hz), 7.65 (1H, d, J = 9.2 Hz). 13C 
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NMR (100 MHz, CDCl3) δ 24.6, 26.4, 28.83, 28.87, 31.1, 33.7, 49.7, 103.9, 115.7, 125.71, 
125.76, 127.1, 127.3, 151.1, 160.8, 178.1. HRMS m/z calcd monoisotopic mass for 
C16H19N3O2Se 365.06425, found: 365.06393.
Synthesis of peptide conjugates
Peptide fragments were prepared by using traditional Fmoc solid phase peptide synthesis on 
Rink amide MBHA resin. In general, protected amino acids (3 eq) were dissolved in DMF 
and activated with HBTU/HOBt (2.8 eq each) in the presence of N-methylmorpholine (9 eq). 
Coupling solutions were added to the resin and shaked for 1 h. The resin was washed 5 times 
with DMF. The completeness of each coupling step was monitored with Kaiser test. The N-
terminal Fmoc group was removed with 20% piperidine solution in DMF (20 min) and the 
resin was washed 5 times with DMF.
A selenadiazole carboxylic acid (3 eq) was activated with HBTU/HOBt (2.8 eq each) in DMF 
in the presence of N-methylmorpholine (9 eq). Coupling solutions were added to the resin and 
shaked for 3 h. The resins were washed 5 times with each solvent (DMF, isopropanol, DCE) 
and dried. Finally the protection groups were removed and the conjugates cleaved from the 
resin by 2 h treatment with a mixture of trifluoroacetic acid, triisopropylsilane and water 
(90:5:5, by volume). The conjugates were purified with C18 reversed phase HPLC and 
lyophilized.
Labelling of peptide conjugates with the fluorescent dye PromoFlour-647
Peptide conjugate (ARC-1601, ARC-1608, ARC-3131 and ARC-3138) and NHS ester of 
PromoFlour-647 were dissolved in DMSO and Et3N. After 3 h reaction the solvents were 
removed in vacuum and the products were purified by HPLC with C18 reverse phase column 
to yield ARC-1602, ARC-1609, ARC-3132 and ARC-3141, respectively.
Synthesis of ARC-3168
ARC-3138 (13 nmol) was treated with Ac2O (2 eq) and Et3N (1 µl) in DMF (50 µl) overnight. 
The solvent was removed in vacuum and the residue was purified by HPLC with C18 reverse 
phase column to yield ARC-3168. 
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1. Piperidine/DMF
2. HBTU/HOBt, N-methylmorpholine, 1 hr
3. TFA, H2O, Triisopropylsilane (90:5:5), 2 hr
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Synthesis of peptide conjugates : ARC-1601
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Synthesis of peptide conjugates : ARC-1602
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1. Piperidine/DMF
2. HBTU/HOBt, N-methylmorpholine, 1 hr
3. TFA, H2O, Triisopropylsilane (90:5:5), 2 hr
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Synthesis of peptide conjugates : ARC-1608
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Synthesis of peptide conjugates : ARC-1609
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1. Piperidine/DMF
2. HBTU/HOBt, N-methylmorpholine, 1 hr
3. TFA, H2O, Triisopropylsilane (90:5:5), 2 hr
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Synthesis of peptide conjugates : ARC-3131
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Synthesis of peptide conjugates : ARC-3132
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Synthesis of peptide conjugates : ARC-3138
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Synthesis of peptide conjugates: ARC-3141
SI (13)
3. UV-Visible absorption spectra of compounds
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Figure S1. UV-Visible spectra of compounds 1, 2, 3 at 0.4 mM concentration (aqueous solution, pH 
7.5).
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4. NMR Data
1
H NMR spectrum of compound 1.
13C NMR spectrum of compound 1.
N
Se
N COOH
N
Se
N COOH
SI (15)
1H NMR spectrum of compound 2.
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5. HPLC data for purified compounds
HPLC separation of the compounds
The mobile phase for gradient HPLC consisted of solution A (0.1% TFA) and solution B 
(0.1% TFA in ACN). The flow rate was 1 ml/min. Linear gradient and elution were started at 
3 min.
Table S1. 
Compound code Molecular formula Gradient speed
ACN%
Retention 
time, tR (min)
Purity, area % 
of HPLC peak
ARC-3131 C58H103N31O9Se 5%-40%/30 min 14.0 100
ARC-3132 C90H139N33O16S2Se 10%-60%/30min 13.7 100
ARC-3138 C46H61N11O21Se 5%-40%/30 min 27.7 100
ARC-3141 C78H97N13O28S2Se 10%-60%/30min 23.3 100
ARC-3168 C48H63N11O22Se 10%-60%/30min 24.5 100
ARC-1601 C55H100N30O9Se 5%-40%/30 min 11.4 100
ARC-1602 C87H136N32O16S2 Se 10%-60%/30min 12.5 100
ARC-1608 C55H100N30O9Se 5%-40%/30 min 10.0 99.2
ARC-1609 C87H136N32O16S2Se 5%-60%/30 min 13.8 100
Chromatograms
ARC-3131
Gradient 5%-40%ACN/30 min
Purity 100%
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ARC-3132
Gradient 10%-60%ACN/30 min
Purity 100%
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ARC-3138
Gradient 5%-40%ACN/30 min
Purity 100%
 
ARC-3141
Gradient 10%-60%ACN/30 min
Purity 100%
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ARC-3168
Gradient 10%-60% ACN/30 min
Purity 100%
ARC-1601
Gradient 5%-40%ACN/30 min
Purity 100%
SI (22)
ARC-1602
Gradient 10%-60%ACN/30 min
Purity 100%
ARC 1608
Gradient 5%-40%ACN/30 min
Purity 98.4%
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ARC 1609
Gradient 10%-60%ACN/30 min
Purity 100%
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6. Structures and HRMS data
Table S2. Compound codes, structures and HRMS data of compounds. Deconvoluted monoisotopic 
masses are presented
Code Structure HRMS 
found
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7. Selectivity data
Table S3. Residual activities (%) of PKs in the presence of ARC-3138 (1 µM). Data of CK2 is 
presented in yellow.
Selectivity testing was performed on the commercial basis at the Division of Signal Transduction 
Therapy, University of Dundee. In the assays ATP was used at a concentration close to the ATP Km 
value of the kinase.
Kinase Residual activity Kinase Residual activity Kinase Residual activity
CK2 20 PRAK 87 PKCz 95
ERK8 53 p38d MAPK 87 STK33 95
Aurora B 60 CK1γ2 87 NUAK1 95
GSK3b 63 CHK1 87 SIK2 95
MLK1 65 SIK3 88 PKCγ 96
TTK 68 p38a MAPK 88 p38b MAPK 96
IGF-1R 69 MKK2 88 TESK1 96
ERK2 70 ERK1 89 OSR1 96
CDK2-Cyclin A 72 PKBb 89 CHK2 98
VEG-FR 72 MAPKAP-K3 89 p38g MAPK 98
EPH-B3 73 EPH-B1 89 EPH-A4 98
PLK1 74 TGFBR1 89 MAP4K5 98
MST4 74 TSSK1 89 RIPK2 98
TIE2 74 IKKb 89 IR 98
IKKe 75 MAP4K3 90 MARK1 99
MLK3 75 HIPK2 90 TAK1 99
BTK 76 PAK5 90 PKBa 99
PIM3 77 JNK3 90 PAK2 100
CLK2 77 TrkA 90 MNK1 100
JAK2 77 DAPK1 90 PAK4 100
BRK 77 IRAK4 90 MNK2 101
RSK1 78 MSK1 91 TTBK2 101
CSK 78 RSK2 91 MST2 101
TAO1 79 CAMK1 91 LKB1 101
ROCK 2 80 EPH-B2 91 BRSK2 101
MST3 80 EIF2AK3 91 CAMKKb 102
Src 81 NEK2a 91 Aurora A 102
SYK 81 PRK2 91 SmMLCK 103
PDK1 81 HER4 92 PDGFRA 103
PKD1 81 PIM2 92 HIPK3 104
SRPK1 81 AMPK (hum) 92 ULK2 105
DYRK2 82 HIPK1 92 IRAK1 105
FGF-R1 82 MARK3 92 IRR 106
MKK6 83 MINK1 92 PHK 106
PKCa 84 DYRK3 92 ABL 106
ERK5 84 TBK1 92 MAPKAP-K2 107
EPH-B4 84 BRSK1 93 PKA 108
JNK2 84 PIM1 93 ASK1 108
EPH-A2 84 MARK4 93 PAK6 108
GCK 84 NEK6 93 S6K1 109
MARK2 85 YES1 94 MPSK1 110
DYRK1A 85 TTBK1 94 MELK 111
MKK1 85 TLK1 94 MEKK1 111
CK1δ 85 Lck 94 DDR2 117
ULK1 86 WNK1 94 CDK9-Cyclin  TI 119
PINK 87 EF2K 95
JNK1 87 SGK1 95
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8. ARC-Lum binding assay
Binding assay with time-gated luminescence intensity detection
The binding curves were measured according to the protocol described previously.4 Briefly, 
all biochemical binding experiments were performed on black low-volume 384-well non-
bonding-surface microplates (Corning #3676) on a PHERAstar platereader (BMG Labtech) 
with TRF optical module [λex = 337 (50) nm, λem = 675 (50) nm] when using the time-
resolved fluorescence measurement mode or with fluorescence anisotropy module [λex = 590 
(50) nm, λem = 675 (50) nm] when using the fluorescence anisotropy readout. The microplates 
were incubated at 30 °C for 20 min before each measurement.
To characterize the binding of luminescence probe ARC-1602, ARC-1609, ARC-3132, 
ARC-3141 to PKAc, Pim-1 and CK2α, the concentration series of kinases (3-fold dilutions) 
were made in the assay buffer and the fixed concentration of luminescent probe was added to 
each well.
In TRF mode, ARC-Lum probes were excited with a flash of the xenon lamp at 337 (50) nm, 
followed by 50 s delay time and subsequent acquisition (150 s) of the luminescence signal 
at 675(50) nm. The data were fitted with the aid of GraphPad Prism software version 5.0 
(GraphPad Software, Inc.) and KD values were calculated using nonlinear regression analysis:
𝑇𝐺𝐿 = 𝐵 + 𝑀 [𝐿𝑡 + 𝐾𝐷 + 𝑘𝐸0 − ￿(𝐿𝑡 + 𝐾𝐷 + 𝑘𝐸0)2 −  4𝐿𝑡 𝑘𝐸02  
(Eq.1)
where B is the background signal; M is the luminescence intensity of the PK/ARC-Lum 
complex; Lt is the total concentration of ARC-Lum; E0 is the nominal concentration of the 
kinase; KD is the dissociation constant between ARC-Lum and PK; k is the fraction of the 
active kinase.
Measurement of luminescence lifetimes
The luminescence lifetimes of complexes of ARC-probes with kinases were measured on a 
PHERAstar platereader using the luminescence decay mode. The complex of ARC-
Lum(Fluo) probe with kinases PKAc, Pim1 or CK2α was excited with a flash of the xenon 
lamp at 337 nm, and the luminescence decay was subsequently recorded. Luminescence 
lifetime was calculated from the decay curves by using exponential decay function with the 
Prism software. Because of long afterglow of xenon flash-lamps minimal delay time of 50 µs 
could be used time-gated measurements.
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Binding curve and decay curve: ARC-1602 and ARC-1609 with PKAc
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e S2. (A) Titration of ARC-1602 or ARC-1609 (both at 10 nM total concentration) with PKAc [λex = 
337 (50) nm, λem = 675 (50) nm]. ARC-1609: KD = 152  46 nM, ARC-1602: KD = 84  30. (B) 
Decay curve of luminescence intensities of ARC-1602 and ARC-1609 in the presence or absence of 
PKAc [λex = 337 (50) nm, λem = 675 (50) nm]. ARC-1602/PKAc: τ = 29  3 µs, ARC-1609/PKAc: τ = 
32  3 µs.
Decay curve: ARC-3132 with PKAc
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Figure S3. Decay curve of luminescence intensity of ARC-3132 (100 nM) in the presence or absence 
of PKAc (300 nM) [λex = 337 (50) nm, λem = 675 (50) nm]. ARC-3132/PKAc: τ = 43  2 µs.
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Decay curve and binding curve: ARC-3141 with CK2α
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Figure S4. (A) Decay curve of luminescence intensities of ARC-3141 (30 nM) in the presence or 
absence of CK2α1-335 (150 nM) [λex = 337(50) nm, λem = 675 (50) nm]. ARC-3141/CK2α1-335: τ = 20  
2 µs. (B) Titration of CK2α1-335 with 5 nM ARC-3141 detected by fluorescence anisotropy [λex = 590 
(50) nm, λem = 675 (50) nm].
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Luminescence intensities: ARC-3138, ARC-3141 with CK2α and 
ARC-3131, ARC-3132 with PKAc
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Figure S5. Luminescence intensities of compounds with and without fluorescent dyes, [λex = 337 (50) 
nm, λem = 675 (50) nm, delay time 50 µs, acquisition time 150 µs, mean of three readings plotted with 
95% confidence interval]. (A) ARC-3138 (200 nM) in the presence or absence of CK2α1-335 (500 nM), 
(B) ARC-3141 (30 nM) in the presence or absence of CK2α1-335 (150 nM), (C) ARC-3131 (200 nM) in 
the presence or absence of PKAc (500 nM), (D) ARC-3132 (30 nM) in the presence or absence of 
PKAc (150 nM).
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9. Inhibition of CK2α by ARC-3138 and ARC-3141
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Figure S6. The inhibitory potencies of ARC-3138 and ARC-3141 were determined by TLC-based 
fluorometric phosphorylation assay as described previously5 at the following concentrations of the 
reaction components: 5-TAMRA-RADDSDDDDD (30 µM), ATP (100 µM), Mg(OAc)2 (10 mM), 
CK2α1-335 (0.6 nM) and 3-fold dilutions of the inhibitors. ARC-3138: IC50 = 600 ± 100 nM; 
ARC-3141: IC50 = 8 ± 5 nM.
10. Displacement of ARC-3138 and ARC-3168 from the complex with 
CK2α
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Figure S7. Displacement assay was carried out as described previously5 at the following 
concentrations of the components: fluorescent probe (2 nM), CK2α1-335 (3 nM) and 3-fold dilutions of 
ARC-3138 or ARC-3168. ARC-3138: IC50 = 600 nM (logIC50 = -6.22 ± 0.06), Kd = 82 ± 22 nM; 
ARC-3168: IC50 = 190 nM (logIC50 = -6.73 ± 0.07), Kd = 34 ± 10 nM.
SI (33)
11. Comparison of novel selenadiazole containing probe ARC-3132 
with previously reported thiophene (ARC-1182) and selenophene 
(ARC-1139) containing probes
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Figure S8. Luminescence intensities of compounds with and without fluorescent dyes [λex = 337 (50) 
nm, λem = 675 (50) nm, delay time 50 µs, acquisition time 150 µs, mean of three readings plotted with 
95% confidence interval]. ARC-3132, ARC-1139 and ARC-1182 (20 nM) in the presence or absence 
of PKAc (200 nM). All three probes are labelled with PromoFluor-647. It is important to note that 
current excitation wavelengths are ideal for ARC-1182 and ARC-1139, but not for ARC-3132.
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